Patents by Inventor John Gatfield

John Gatfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THIAZOLIDIN-4-ONE AND [1,3]-THIAZINAN-4-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20120088759
    Abstract: The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R3 and R4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatment of diseases related to the orexin system. The present invention also relates to novel thiazolidin-4-one compounds of formula (II) and their use as pharmaceuticals, pharmaceutical compositions containing one or more compounds of formula (II), and especially their use as orexin receptor antagonists.
    Type: Application
    Filed: May 11, 2010
    Publication date: April 12, 2012
    Inventors: Hamed Aissaoui, Christoph Boss, Christine Brotschi, Markus Gude, John Gatfield, Romain Siegrist, Thierry Sifferlen, Jodi T. Williams
  • TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20110086889
    Abstract: The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R1, R2 and R3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.
    Type: Application
    Filed: June 10, 2009
    Publication date: April 14, 2011
    Inventors: Hamed Aissaoui, Christoph Boss, Christine Brotschi, John Gatfield, Ralf Koberstein, Romain Siegrist, Thierry Sifferlen, Jodi Williams
  • ENDOTHELIN RECEPTOR ANTAGONISTS FOR EARLY STAGE IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20100022568
    Abstract: This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis.
    Type: Application
    Filed: April 12, 2007
    Publication date: January 28, 2010
    Applicant: Actelion Pharmaceeuticals Ltd.
    Inventors: Martine Clozel, John Gatfield, Sebastien Roux